US SEC Trading Suspension Halt Orders — June 25, 2026

Successfully regained Nasdaq compliance after filing delinquent 10-K and 10-Q. The removal of the delisting overhang removes a significant overhang. However, no insider buying or positive guidance was associated with the cure, suggesting the stock may lack catalysts. [NEUTRAL/BULLISH]

Resolution of a procedural deficiency (late filing) rather than a fundamental business issue. This is a positive signal for listing status but provides no insight into underlying business performance or growth.

Received a Bid Price Deficiency Notice on June 25, 2026. This is a direct, immediate threat to its Nasdaq listing and signals significant selling pressure or a depressed valuation.

The stock price has traded below $1.00 for 30 consecutive days (May 12 to June 24). This sustained weakness indicates a lack of buying support and potential structural issues with the stock's market value.

The company has a 180-day cure period until Dec 22, 2026, with potential for a second 180-day extension. This provides a long runway, reducing the immediate risk of a delisting but prolonging the uncertainty. [BEARISH - extended but not elimated risk]

The company is 'exploring options' including a potential reverse stock split. A reverse split is often viewed negatively by the market as it signals a weak stock price and can lead to further selling pressure post-split.

To regain compliance, the closing bid price must be at least $1.00 for 10 consecutive days. This is a relatively low bar, but the sustained failure to achieve it highlights the depth of the problem.

The primary risk is that the company fails to cure the bid price deficiency by the deadline, leading to delisting from Nasdaq. The loss of exchange listing would materially impact liquidity, access to capital, and investor confidence.

The company's intention to explore a reverse stock split is a significant red flag. While it might mechanically cure the price deficiency, it does not address the fundamental issue of low market valuation and often destroys shareholder value by concentrating selling pressure.

The negative sentiment from the 8-K filing (assessed as 'negative') is a self-reinforcing risk. The disclosure of the delisting notice can scare away institutional investors and make it harder for the company to raise capital at a favorable valuation.

Unlike GITS, which resolved a filing issue, Heron's problem is a depressed stock price. Without a strong business catalyst (e.g., a new product approval, partnership, or revenue beat) to drive the stock price above $1.00, a reverse split appears to be the only path, which is a weak remedy.

While compliant, the fact that the company was delinquent on both its 10-K and 10-Q could raise questions among investors about internal controls and the quality of its management. There is a risk of future recurrence.

The filing comes with no positive forward-looking statements, no insider buying, and no capital allocation plan (e.g., buybacks) to support the stock. This suggests management may be struggling to find a market-friendly solution.

The immediate delisting risk is gone. For investors who were short the stock on delisting fears or avoided it, this is a catalyst to re-evaluate the company on its own merit without the overhang of non-compliance.

If the company announces a reverse stock split, the stock may temporarily trade up to the $1.00+ level to meet the compliance rule. A very short-term, event-driven trade could exist for quick capital.

The ongoing delisting crisis could attract activist investors who see an opportunity to force management to take more drastic value-unlocking actions (e.g., sale of the company, major restructuring) to save the listing.

With the compliance notice, GITS is no longer a 'distressed' filing company. This allows it to be considered for inclusion in indices or ETFs that require good listing standing, potentially bringing in new institutional buyers.

The two filings illustrate the two primary paths to Nasdaq non-compliance: procedural (late filings) and fundamental (bid price). Procedural issues can be cured administratively, while price issues require market value recivery, which is far more difficult.

For Heron, the delisting risk is not imminent but prolonged (up to 12 months with extensions). This creates a 'dead zone' for the stock where it can trade at depressed levels with a constant overhang, deterring long-term investment.

The mention of a reverse split is a red flag. It is a cosmetic fix that does not change the business fundamentals and often precedes further declines.

The removal of a delisting notice is a clear positive catalyst. It allows investors to focus on the company's business operations and future prospects without the drag of regulatory uncertainty.

In both filings, there is zero mention of insider buying to support the stock price (or confidence during the compliance process). In delisting scenarios, the absence of insider buying is a strong bearish signal, suggesting management itself is not confident in a recovery.

Monitor for any 8-K filings regarding the outcome of its 'exploration of options'. A decision on a reverse stock split or a potential equity raise will be a material event. Watch for any insider buying (unlikely but would be a massive positive signal). [Immediate]

The stock price will be the key daily monitor. Any close above $1.00 for even one day would be a significant short-term positive, while a continued decline would accelerate the risk. [Ongoing]

Watch for the next quarterly earnings filing (Form 10-Q) to ensure the company maintains its compliance and to get the first clear look at its financial performance. [Next quarter]

The first 180-day cure deadline is December 22, 2026. If the stock is still below $1.00 by Nov/Dec, the company will likely announce a reverse split, which is a critical catalyst point.

Scheduled events like earnings calls will be critical. The company will need to provide strong guidance to justify a stock price above $1.00 without a reverse split. The tone of the call will be a key sentiment indicator.

The initial delinquency notice date was April 16, 2026. Analyse filings around that period to see if any insider selling preceded the notice, which could indicate that the filing issue was known internally.

Monitor the broader market and sector sentiment for small-cap biotech (Heron) and technology (GITS). A sector-wide sell-off could make it harder for either company to maintain a healthy stock price.